Abstract
Polygenic risk scores (PRSs) have recently been used to inform reproductive decision-making in the context of embryonic screening. While this is yet to be widespread, it is contested and raises several challenges. This article provides an overview of some of the ethical considerations that arise with using PRSs for embryo screening and offers a series of regulatory considerations for jurisdictions that may wish to permit this in the future. These regulatory considerations cover possible regulators and regulatory tools, eligibility criteria, information and education requirements and the need for ongoing refinement of the relevant technology, research and consultation.